Literature DB >> 15147144

Intravenous immunoglobulin (IVIG): modes of action in the clinical management of recurrent pregnancy loss (RPL) and selected autoimmune disorders.

Charles O A Omwandho1, Susanne E M Gruessner, Timothy K Roberts, Hans Rudolf Tinneberg.   

Abstract

Recurrent pregnancy loss has been associated with autoimmune responses to membrane phospholipids and alloimmune reactions against paternally derived molecules on the trophoblast. The problem is psychologically and economically stressful as it undermines the capacity of some couples to reproduce and participate effectively in the day-to-day economic activities. This article reviews the adoption of intravenous immunoglobulin as a form of therapy for the clinical management of recurrent pregnancy loss and of selected autoimmune disorders. Side effects, contraindications and safety of use are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15147144     DOI: 10.1515/CCLM.2004.065

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  2 in total

Review 1.  Intravenous immunoglobulin and recurrent pregnancy loss.

Authors:  Howard J A Carp; Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

2.  Treatment with low doses of polyclonal immunoglobulin improves B cell function during immune reconstitution in a murine model.

Authors:  Ana Barahona Afonso; Lígia Neves Justo; Ana Cristina Queirós; Constantin Fesel; Maria Salomé Cabral; Maria Gomes da Silva; Luis Porrata; Svetomir Markovic; Ana Elisabete Pires; Cristina João
Journal:  J Clin Immunol       Date:  2012-09-30       Impact factor: 8.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.